Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer

J. N. Ingle, V. J. Suman, V. C. Jordan, M. Dowsett

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Numerous comparative clinical trials have been conducted evaluating combination hormonal therapy involving the aromatase inhibitor aminoglutethimide, but there is no evidence for any superiority of this approach over single-agent therapy alone. The advent of new aromatase inhibitors with greater potency, selectivity, and better tolerability has prompted a reconsideration of the combined therapy approach, with attention being focused on pharmacologic and endocrinologic clinical research. The value of combining newer aromatase inhibitors with other hormonal agents remains to be established.

Original languageEnglish (US)
Pages (from-to)265-269
Number of pages5
JournalEndocrine-Related Cancer
Volume6
Issue number2
DOIs
StatePublished - Jun 1 1999

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer'. Together they form a unique fingerprint.

  • Cite this